Market Research Logo

Global Diabetic Retinopathy Market 2015-2019

Global Diabetic Retinopathy Market 2015-2019

About Diabetic Retinopathy

Diabetic retinopathy is a disorder of the eye that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye on which images are formed. Long-term diabetes affects the retina as high blood glucose levels can damage the tiny blood vessels in the retina. Diabetic retinopathy is broadly classified into non-proliferative diabetic retinopathy and proliferative retinopathy. Treatment for diabetic retinopathy depends on the stage of the disease and is directed toward slowing down or stopping the progression of the disease. Laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy are some of the available treatments. One feature of diabetic retinopathy is diabetic macular edema. This is a serious medical condition involving leakage of fluid from the minute, delicate, and previously injured blood vessels located at the back of the eye, which then collects in the macula. This results in inflammation of tissue and blurry vision.

TechNavio's analysts forecast the global diabetic retinopathy market to grow at a CAGR of 6.89% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global diabetic retinopathy market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of prescribed as well as off-label drugs available in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the four major vendors in the market. In addition, it discusses the major drivers that influence the growth and the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

TechNavio's report, Global Diabetic Retinopathy Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global diabetic retinopathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions

  • Americas
  • APAC
  • EMEA
Key Vendors
  • Bayer
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals
Other Prominent Vendors
  • Actavis
  • Alimera Sciences
  • Ampio Pharmaceuticals
  • Antisense Therapeutics
  • BCN Peptides
  • Boehringer Ingelheim
  • Glycadia
  • iCo Therapeutics
  • Isis Pharmaceuticals
  • Kowa Group
  • Lpath
  • Numoda Capital
  • Ohr Pharmaceutical
  • OPKO Health
  • Parexel International
  • Promedior
  • pSivida
  • Quark Pharmaceuticals
  • R-Tech Ueno
  • Sirnaomics
  • ThromboGenics
Market Driver
  • Growth in patient population
  • For a full, detailed list, view our report
Market Challenge
  • Availability of effective surgical treatments
  • For a full, detailed list, view our report
Market Trend
  • Launch of novel agents
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Diabetic Retinopathy Market 2015-2019

Technavio recognizes the following companies as the key players in the Global diabetic retinopathy market: Bayer AG, F. Hoffmann-La Roche Ltd. Novartis International AG and Regeneron Pharmaceuticals Inc

Other Prominent Vendors in the market are: Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, OPKO Health, Ohr Pharmaceutical, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics and ThromboGenics

Commenting on the report, an analyst from Technavio’s team said: “Launch of novel drugs is one of the key trends being witnessed in the market. The drug pipeline for diabetic retinopathy contains many promising therapies, with a few in the clinical and pre-clinical development stages. The market also has many drugs in the pipeline, including FIC drugs with disease-modifying properties and drugs with better safety and efficacy profiles.”

According to the report, the improvement in the diagnostic procedures is expected to predominantly drive the market. Visual acuity, dilated eye, optical medical imaging, and eye pressure tests are the existing diagnostic tests used by doctors to confirm the presence of diabetic retinopathy.

Further, the report states that availability of effective surgical treatments is a major challenge that the market faces. Specific therapies are required for diabetic retinopathy because of the potential severity of the disease at a later stage, such as proliferative diabetic retinopathy and retinal detachment.

Companies Mentioned

Bayer AG, F Hoffmann-La Roche Ltd. Novartis International AG and Regeneron Pharmaceuticals Inc, Actavis, Alimera Sciences, Ampio Pharmaceuticals, Antisense Therapeutics, BCN Peptides, Boehringer Ingelheim, Glycadia, iCo Therapeutics, Isis Pharmaceuticals, Kowa Group, Lpath, Numoda Capital, OPKO Health, Ohr Pharmaceutical, Parexel International, Promedior, pSivida, Quark Pharmaceuticals, R-Tech Ueno, Sirnaomics, ThromboGenics

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
    • Product Profiles
      • Lucentis
      • Eylea
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Understanding the Disease
    • Etiology
      • Elevated Blood Glucose
      • Ischemia
      • Hypoxia
      • Neovascularization
      • Increased Permeability of Retinal Vessels
        • Table Development of Diabetic Retinopathy
    • Diagnosis
      • Retinal Photography
      • Fluorescein Angiography
      • Optical Coherence Tomography
    • Classification
      • Table Classification of Diabetic Retinopathy
      • Proliferative Diabetic Retinopathy
      • Non-proliferative Diabetic Retinopathy
    • Epidemiology
    • Management
      • Anti-VEGF Therapy
      • Intraocular Steroid Injection
      • Laser Surgery
      • Vitrectomy
  • Market Landscape
    • Market Overview
      • Table Snapshot of Global Diabetic Retinopathy Market
    • Market Size and Forecast
      • Table Global Diabetic Retinopathy Market 2014-2019 ($ millions)
    • Key Takeaways
      • Table Key Takeaways: Global Diabetic Retinopathy Market
    • Five Forces Analysis
  • Pipeline Portfolio
  • Market Segmentation by Type of Molecule
    • Table Global Diabetic Retinopathy Market by Type of Molecule
    • Biologics
    • Corticosteroids
      • Table Segmentation of Global Diabetic Retinopathy Market by Type of Molecule 2014
  • Market Segmentation by Route of Administration
    • Table Global Diabetic Retinopathy Market by Route of Administration
    • Intravitreal
    • Intravenous
      • Table Segmentation of Global Diabetic Retinopathy Market by Route of Administration 2014
  • Geographical Segmentation
    • Table Segmentation of Global Diabetic Retinopathy Market by Geography 2014
    • Table Segmentation of Global Diabetic Retinopathy Market by Geography 2019
    • Diabetic Retinopathy Market in Americas
      • Market Size and Forecast
        • Table Diabetic Retinopathy Market in Americas 2014-2019 ($ millions)
    • Diabetic Retinopathy Market in EMEA
      • Market Size and Forecast
        • Table Diabetic Retinopathy Market in EMEA 2014-2019 ($ millions)
    • Diabetic Retinopathy Market in APAC
      • Market Size and Forecast
        • Table Diabetic Retinopathy Market in APAC 2014-2019 ($ millions)
  • Buying Criteria
  • Market Growth Drivers
    • Table Major Drivers of Global Diabetic Retinopathy Market
  • Drivers and their Impact
  • Market Challenges
    • Table Major Challenges in Global Diabetic Retinopathy Market
  • Impact of Drivers and Challenges
  • Market Trends
    • Table Major Trends in Global Diabetic Retinopathy Market
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Novartis
        • Table Novartis: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
        • Table Key Takeaways: Novartis
      • F. Hoffmann-La Roche
        • Table F. Hoffmann-La Roche: YoY Revenue and Growth Rate for Lucentis 2011-2014 ($ millions)
        • Table Key Takeaways: F. Hoffmann-La Roche
      • Regeneron Pharmaceuticals
        • Table Regeneron Pharmaceuticals: YoY Revenue and Growth Rate for Eylea 2011-2014 ($ millions)
        • Table Key Takeaways: Regeneron Pharmaceuticals
      • Bayer
        • Table Bayer: YoY Revenue and Growth Rate for Eylea 2012-2014 ($ millions)
        • Table Key Takeaways: Bayer
    • Other and Future Prominent Vendors
  • Key Vendor Analysis
    • Bayer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2014
        • Table Bayer: Business Segmentation by Revenue 2014
      • Business Segmentation by Revenue 2013 and 2014
        • Table Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
      • Geographical Segmentation by Revenue 2014
        • Table Bayer: Geographical Segmentation by Revenue 2014
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • F. Hoffmann-La Roche
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table F. Hoffmann-La Roche: Pharmaceutical Sales by Geography 2013
        • Table F. Hoffmann-La Roche: Diagnostics Sales by Geography 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
      • Sales by Geography
        • Table Novartis: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Regeneron Pharmaceuticals
      • Key Facts
      • Business Overview
      • Product Segmentation
        • Table Regeneron Pharmaceuticals: Product Segmentation
      • Revenue Product Segmentation
        • Table Regeneron Pharmaceuticals: Revenue Product Segmentation 2013
      • Business Strategy
      • Key Information
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report